Ann: Notice of Annual General Meeting/Proxy Form, page-20

SDX may turn out to be worth while but IMO the price BD1 paid was way over the top considering sub 100k in income per quarter.
IMO it had more to do with getting Williams and co their money back from SDX.
I was hoping they would leave most, if not all the SDX management behind.
We have a pretty large MC for a company 18 -24 months away from having a product and basically, reading the quarterly again, they are bringing everything to Melbourne which as we all know has been locked down so I expect all that to be delayed as well.

What I'm looking for going forward.
That Griffith Uni get the independent test done in the time the quarterly said.
They get all the lab up and running in Melbourne.
They get on with Breast and Lung cancer trials.
I'd like to see a couple of management positions evaporate. We are way too top heavy and there is plenty of experience on the BD1 side IMO.